{
    "name": "aflibercept intravitreal",
    "comment": "Rx",
    "other_names": [
        "Eylea"
    ],
    "classes": [
        "Macular Degeneration Agents",
        "Ophthalmics",
        "VEGF Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/eylea-aflibercept-intravitreal-999705",
    "pregnancy": {
        "common": [
            "Adequate and well-controlled studies have not been conducted in pregnant women; aflibercept produced adverse embryofetal effects in rabbits, including external, visceral, and skeletal malformations",
            "Animal reproduction studies not always predictive of human response; not known whether product can cause fetal harm when administered to pregnant woman; based on anti-VEGF mechanism of action for aflibercept, treatment may pose a risk to human embryofetal development"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential are advised to use effective contraception prior to initial dose, during treatment, and for at least 3 months after last intravitreal injection"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "There are no data regarding effects on human fertility; aflibercept adversely affected female and male reproductive systems in cynomolgus monkeys when administered by intravenous injection at a dose approximately 1500 times higher than systemic level observed humans with an intravitreal dose of 2 mg; a No Observed Adverse Effect Level (NOAEL) was not identified; aflibercept produced fetal malformations at all doses assessed in rabbits and the fetal NOAEL was <0.1 mg/kg; findings were reversible within 20 weeks after cessation of treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding presence of aflibercept in human milk, effects on breastfed infant, or on milk production/excretion; because many drugs are excreted in human milk, and potential for absorption and harm to infant growth and development exists, therapy is not recommended during breastfeeding",
            "Developmental and health benefits of breastfeeding should be considered along with mother's clinical need for therapy and potential adverse effects on breastfed child"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity reactions ",
                "Ocular or periocular infection",
                "Active intraocular inflammation"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Endophthalmitis and retinal detachments reported with intravitreal injections; instruct patients and/or caregivers to report any signs and/or symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately",
                "Acute increases in intraocular pressure (IOP) observed within 60 minutes of intravitreal injection; sustained increases also reported after repeat dosing; monitor and manage IOP and perfusion of optic nerve head",
                "Risk of arterial thromboembolic events (eg, nonfatal stroke, nonfatal myocardial infarction, or vascular death) following intravitreal use of VEGF inhibitors (incidence over 1 yr varies depending on the study ranging from 1.5-6.4%); no thromboembolic events reported within the first 6 months of RVO studies",
                "Hypersensitivity reactions may present as severe intraocular inflammation",
                "Females of reproductive potential should use effective contraception prior to initial dose, during treatment, and for at least 3 months after last intravitreal injection "
            ],
            "specific": [
                {
                    "type": "Extended monitoring and additional treatment in ROP ",
                    "description": [
                        "Reactivation of abnormal angiogenesis and tortuosity may occur following treatment ",
                        "Monitor infants closely after injection until retinal vascularization has completed or until the examiner is assured that reactivation of ROP will not occur ",
                        "In infants with ROP, treatment necessitates extended periods of ROP monitoring and additional injections and/or laser treatments may be necessary "
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Conjunctival hemorrhage",
            "percent": "12-31"
        },
        {
            "name": "Eye pain",
            "percent": "9-13"
        },
        {
            "name": "Cataract",
            "percent": "1-13"
        },
        {
            "name": "Increased IOP",
            "percent": "5-9"
        },
        {
            "name": "Vitreous detachment",
            "percent": "1-8"
        },
        {
            "name": "Vitreous floaters",
            "percent": "6-8"
        },
        {
            "name": "Corneal epithelium defect",
            "percent": "2-7"
        },
        {
            "name": "Retinal pigment epithelium detachment",
            "percent": "3-5"
        },
        {
            "name": "Ocular hyperemia",
            "percent": "42-5"
        },
        {
            "name": "Foreign body sensation in eyes",
            "percent": "3-4"
        },
        {
            "name": "Lacrimation increased",
            "percent": "3-4"
        },
        {
            "name": "Blurred vision",
            "percent": "1-4"
        },
        {
            "name": "Intraocular inflammation",
            "percent": "1-3"
        },
        {
            "name": "Injection site pain",
            "percent": "1-3"
        },
        {
            "name": "Retinal pigment epithelium tear",
            "percent": "2"
        },
        {
            "name": "Injection site hemorrhage",
            "percent": "1-2"
        },
        {
            "name": "Eyelid edema",
            "percent": "1-2"
        },
        {
            "name": "Corneal edema",
            "percent": "1"
        },
        {
            "name": "Conjunctival hemorrhage",
            "percent": "5-9"
        },
        {
            "name": "Retinal detachment",
            "percent": "5-6"
        },
        {
            "name": "Increased IOP",
            "percent": "4"
        },
        {
            "name": "Eyelid edema",
            "percent": "3"
        },
        {
            "name": "Corneal epithelium defect",
            "percent": "1"
        },
        {
            "name": "Corneal edema",
            "percent": "1"
        },
        {
            "name": "Lenticular opacities",
            "percent": "1"
        }
    ]
}